I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I Mab Announces Ind Approval From China Nmpa For Phase 2 Clinical Trial Of Enoblituzumab In Combination With Pembrolizumab In Solid Tumors

Facebook Comments

Leave a Reply

CommentLuv badge